Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)‘s stock had its “hold” rating reissued by equities researchers at Cowen and Company in a report released on Thursday.

The analysts wrote, “Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of.””

A number of other analysts also recently weighed in on the company. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Finally, ValuEngine downgraded Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). During the same quarter in the previous year, the business earned ($0.62) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Sunesis Pharmaceuticals’ (SNSS) “Hold” Rating Reaffirmed at Cowen and Company” was first reported by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/02/sunesis-pharmaceuticals-snss-hold-rating-reaffirmed-at-cowen-and-company.html.

In other Sunesis Pharmaceuticals news, Director Dayton Misfeldt acquired 400,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $800,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 10.21% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. NEA Management Company LLC lifted its position in shares of Sunesis Pharmaceuticals by 36.9% during the 4th quarter. NEA Management Company LLC now owns 7,789,644 shares of the biopharmaceutical company’s stock worth $7,011,000 after buying an additional 2,100,000 shares during the last quarter. TFS Capital LLC bought a new stake in shares of Sunesis Pharmaceuticals during the 1st quarter worth $158,000. Renaissance Technologies LLC lifted its position in shares of Sunesis Pharmaceuticals by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 110,581 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 16,000 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Sunesis Pharmaceuticals during the 1st quarter worth $173,000. Finally, Neuberger Berman Group LLC lifted its position in shares of Sunesis Pharmaceuticals by 16.6% during the 1st quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 57.56% of the company’s stock.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.